The estimated Net Worth of Steven Nichtberger is at least $5.7 Millón dollars as of 19 October 2022. Steven Nichtberger owns over 8,127 units of Cabaletta Bio Inc stock worth over $4,202,418 and over the last 5 years he sold CABA stock worth over $0. In addition, he makes $1,499,000 as Chairman of the Board, President, Chief Executive Officer y Co-Founder at Cabaletta Bio Inc.
Sign up
Steven Nichtberger CABA stock SEC Form 4 insiders trading
Steven has made over 3 trades of the Cabaletta Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 8,127 units of CABA stock worth $10,159 on 19 October 2022.
The largest trade he's ever made was buying 141,873 units of Cabaletta Bio Inc stock on 18 October 2022 worth over $140,454. On average, Steven trades about 18,182 units every 24 days since 2019. As of 19 October 2022 he still owns at least 986,483 units of Cabaletta Bio Inc stock.
You can see the complete history of Steven Nichtberger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Nichtberger biography
Dr. Steven Nichtberger M.D. serves as Chairman of the Board, President, Chief Executive Officer, Co-Founder of the Company. He is also serves as managing partner of GBF Advisors, LLC, a company that provides advisory services to healthcare companies, investors, and leading academic scientists and is an adjunct professor at The Wharton School at the University of Pennsylvania. He is the chairman of the board of directors of ControlRad, Inc., a medical device company developing and marketing products to reduce radiation exposure associated with medical procedures, a member of the board of directors of the BioAdvance Greenhouse Fund, which provides funding to startup life sciences companies in southeastern Pennsylvania, and a member of the board of governors of Main Line Health, a not-for-profit health system. Dr. Nichtberger is also a venture advisor for the Israel Biotech Fund. Previously, he was the president, chief executive officer, and a member of the board of directors of Tengion, Inc. from 2004 to 2011. Earlier in his career, Dr. Nichtberger served in various commercial leadership positions at Merck from 1995 to 2003. He has previously served as a member of the boards of directors of the Alliance for Regenerative Medicine (as a founding member), Pennsylvania Bio including as chairman, and Biotechnology Industry Organization. He was also a member of the board of overseers for the School of Arts & Sciences at the University of Pennsylvania for over a decade. Dr. Nichtberger received his M.D. from the State University of New York at Buffalo, his B.S. from The Wharton School at the University of Pennsylvania and his B.A. from the University of Pennsylvania. He completed an internship, residency and fellowship in the Department of Medicine and the Division of Cardiology of the Mount Sinai Medical Center. Dr. Nichtberger also serves as a member of our board of directors.
What is the salary of Steven Nichtberger?
As the Chairman of the Board, President, Chief Executive Officer y Co-Founder of Cabaletta Bio Inc, the total compensation of Steven Nichtberger at Cabaletta Bio Inc is $1,499,000. There are 1 executives at Cabaletta Bio Inc getting paid more, with Anup Marda having the highest compensation of $1,528,630.
What's Steven Nichtberger's mailing address?
Steven's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Insiders trading at Cabaletta Bio Inc
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... y James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
What does Cabaletta Bio Inc do?
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
What does Cabaletta Bio Inc's logo look like?
Complete history of Steven Nichtberger stock trades at Cabaletta Bio Inc
Cabaletta Bio Inc executives and stock owners
Cabaletta Bio Inc executives and other stock owners filed with the SEC include:
-
Anup Marda,
Chief Financial Officer -
Steven Nichtberger,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Gwendolyn Binder-Scholl,
Executive Vice President, Science & Technology -
Dr. Steven A. Nichtberger M.D.,
Co-Founder, Chairman, CEO & Pres -
Dr. Steven A. Nichtberger,
Co-Founder, Chairman, CEO & Pres -
Dr. David J. Chang M.D., M.P.H.,
Chief Medical Officer -
Dr. Gwendolyn K. Binder,
Exec. VP of Science & Technology -
Richard Henriques,
Independent Director -
Catherine Bollard,
Independent Director -
Mark Simon,
Independent Director -
Brian Daniels,
Independent Director -
David Chang,
Chief Medical Officer -
J. Brian Stalter,
General Counsel -
Michael Gerard J.D.,
Gen. Counsel & Sec. -
Heather Harte-Hall M.Sc.,
Chief Compliance Officer -
Michael Gerard,
Gen. Counsel -
Dr. Samik Basu M.D.,
Chief Scientific Officer -
Martha O'Connor,
Chief HR Officer -
J. Brian Stalter J.D.,
Gen. Counsel -
Dr. Aimee Payne M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Dr. Michael C. Milone M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Anup Marda M.B.A.,
Chief Financial Officer -
Shawn Tomasello,
-
Scott C. Brun,
-
Gwendolyn Binder,
See Remarks -
Arun Das,
Chief Business Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt Iv, ...,
-
Ventures V, L.P.5 Am Opport...,
-
Michael Gerard,
General Counsel